Autolus Therapeutics

Autolus Therapeutics

Biotechnology
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

$303.6M

Market Cap • 11/16/2026

2018

(8 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United Kingdom

United Kingdom

Country

Valuation

P/B

11,1

P/S

2,2

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

0,1

EPS

—

Market Cap

Market Cap

303,6M

EV

448,5M

EV/Revenue

3,3

EV/EBITDA

-2,2

EV/EBIT

-2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-1,6B

Profitability

Gross Margin

35,8%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

84,1%

Capex/Revenue

3,3%

Capex/D&A

39,8%

Capex/OCF

-27,9%

SBC/OCF

—

% PPE

25,5%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

146,6%

CAGR Op. Income 5Y

5,7%

CAGR Net Income 5Y

12,3%

CAGR EPS 5Y

-15,9%

CAGR OCF 5Y

-35,2%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

0,8

Quick Ratio

0,1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium